Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2동종 2회 용량 ChAdOx1 대 ChAdOx1 및 BNT162b2를 사용한 이종 백신의 비교 효과 및 안전성Article Published on 2022-03-232022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, [키워드] 95% confidence interval age Analysis BNT162b2 ChAdOx1 Cohort cohort analysis Comparative COVID-19 Delta dose Effectiveness first dose followed by generate group hazard ratio Heterologous homologous immune response Infection Linked data MOST negative control occurred outcome outcomes Phase 2 predominant randomised receiving resulting Safe SARS-CoV-2 variant second dose Sex Spain suggested These data Trial trials two group two groups vaccination vaccination schedule [DOI] 10.1038/s41467-022-29301-9 PMC 바로가기 [Article Type] Article
Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 5050세 이상의 사람들에서 Covid-19에 대한 BNT162b2 및 ChAdOx1 백신의 비교 효과Article Published on 2022-03-212022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, 치료법, [키워드] 95% CI BNT162b2 booster ChAdOx1 ChAdOx1 vaccine Comparative Cox model delta variant dominant dose Effectiveness Efficacy hazard ratio head Head-to-head comparison hospitalisation Infection inverse lower risk mRNA of BNT162b2 Older participant persist Population Probability risk SARS-COV-2 infection study period Trial UK biobank vaccination Vaccine Vaccines Weighting [DOI] 10.1038/s41467-022-29159-x PMC 바로가기 [Article Type] Article
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2BNT162b2(화이자-바이오엔텍) 및 ChAdOx1 nCoV-19(옥스포드-아스트라제네카) 백신의 SARS-CoV-2 델타 변이형(B.1.617.2) 감염에 대한 감수성 감소 효과Article Published on 2022-03-202022-09-11 Journal: BMC Infectious Diseases [Category] SARS, 변종, 치료기술, [키워드] Action Alpha Alpha variant assumed B.1.1.7 B.1.617.2 BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Combined Complete Course COVID-19 COVID-19 vaccination programme credible interval delta variant dose doses effective Effectiveness Epidemic explain finding health record Infection Infectious disease intelligence modelling Oxford Oxford-AstraZeneca PCR Pfizer-BioNTech Population predominant provide public health receiving reduce reducing resource SARS-CoV-2 SARS-COV-2 infection single dose Single-dose SIR susceptibility susceptibility to infection symptomatic and asymptomatic Transmission Vaccine variant [DOI] 10.1186/s12879-022-07239-z PMC 바로가기 [Article Type] Article
Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination증례 보고서: ChAdOx1 nCoV-19 백신 접종 후 심각한 횡문근 융해증 및 다기관 부전Case Reports Published on 2022-03-172022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] accelerated Anakinra assumption biologic Bone marrow Case report ChAdOx1 ChAdOx1 nCoV-19 characterized creatine phosphokinase cytokine Cytokine storm Deterioration dramatic increase drug eculizumab failure first dose had no healthy hypoglycemia immunosuppressive Infection inflammatory markers kidney liver lung multi organ failure nine occur occurred patient death patients with SARS-CoV-2 PCT physician procalcitonin rapid increase reported resulting rhabdomyolysis Risk factors SARS-CoV-2 SARS-CoV2 Shock Skeletal muscle Steroids therapy Treatment vaccination vaccine administration [DOI] 10.3389/fimmu.2022.845496 PMC 바로가기 [Article Type] Case Reports
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab인플릭시맙과 베돌리주맙으로 치료받은 염증성 장질환 환자에서 SARS-CoV-2 백신 2회 투여 후 항체 붕괴, T 세포 면역 및 돌발성 감염Article Published on 2022-03-162022-09-11 Journal: Nature Communications [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] anti-S anti-TNF antibody antibody concentration BNT162b2 Breakthrough infection breakthrough infections ChAdOx1 ChAdOx1 nCoV-19 Concentration dose drug geometric mean half-live immune responses Immunity impair induce Inflammatory bowel disease infliximab Influenza influenza vaccination integrin nCoV Necrosis of BNT162b2 p value Patient patients patients treated pneumococcal predicted protective immunity RBD required respiratory respiratory infection risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine sustained T cell T cell response treated treatment groups tumour necrosis factor U/mL vaccination vaccination schedule vaccine doses vaccine-induced immune response vedolizumab [DOI] 10.1038/s41467-022-28517-z PMC 바로가기 [Article Type] Article
Acute Calcium Pyrophosphate Crystal Arthritis of the Wrist Elicited by Anti-COVID-19 Vaccination After Carpal Tunnel Release손목 터널 방출 후 Anti-COVID-19 예방 접종으로 유발된 급성 피로인산칼슘 결정 관절염 손목염Case Reports Published on 2022-03-122022-09-11 Journal: The American journal of case reports [Category] SARS, 유전자 메커니즘, [키워드] administration anatomical Arthritis association calcium Calcium pyrophosphate carpal carpal canal Carpal Tunnel carpal tunnel syndrome Case report ChAdOx1 ChAdOx1 nCoV-19 China coding COVID-19 infection CPP crystal develop disease Efficacy effort Exacerbation expression Factor followed by illness immune response include mechanism Most patient Most patients Oxford-AstraZeneca Pain pandemic Patient phase 3 trial Phase 3 trials presenting Pyrophosphate Release required resolution of symptoms second dose severe pain shown Spike protein stiffness stimulate surgical swelling Symptom syndrome the SARS-CoV-2 the vaccine Treatment triggered Tunnel vaccination Vaccine variety wrist [DOI] 10.12659/AJCR.934833 PMC 바로가기 [Article Type] Case Reports
COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland폴란드 교사에게 투여된 ChAdOx1 백신의 반응성 및 면역원성의 맥락에서 COVID-19 백신 접종Article Published on 2022-03-062022-09-10 Journal: International Journal of Environmental Research an [Category] MERS, SARS, 진단, 치료기술, [키워드] adverse effects Adverse reaction Adverse reactions age All participant All participants anti-RBD Anti-RBD IgG Antibody Response ChAdOx1 ChAdOx1 vaccine ChAdOx1-S chills Context COVID-19 demonstrated detectable determinants dose dosing interval Efficacy ENhance female first dose headache immunogenicity immunologic response immunologic responses individual Infection interval malaise male mRNA multivariate logistic regression offered Older participant Participants Poland predictor RBD reactogenicity Receptor-binding domain Region reported required SARS-CoV-2 SARS-COV-2 infection Serological testing Side effect Side effects Support teacher teachers the mean the median the receptor-binding domain Tolerability uninfected Vaccine were measured [DOI] 10.3390/ijerph19053111 PMC 바로가기 [Article Type] Article
Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period3개월 동안의 ChAdOx1 nCoV-19 및 BNT162b2 백신과 2019년 천연 코로나바이러스 감염에 대한 면역 반응Article Published on 2022-03-022022-09-12 Journal: The Journal of Infectious Diseases [Category] MERS, SARS, 진단, [키워드] analyzed antibody Antibody Response BNT162b2 BNT162b2 vaccine ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine ChAdOx1 vaccine coronavirus disease COVID-19 enrolled healthcare worker IgG immune response Immunoglobulin infections natural natural infection neutralizing antibody Neutralizing antibody titer of BNT162b2 over Patient Period response S1 IgG second dose second dose. significantly T cells T-cell Response T-cell responses Vaccine vaccinee vaccinees [DOI] 10.1093/infdis/jiab579 PMC 바로가기 [Article Type] Article
Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19경증 또는 중증 COVID-19 환자와 COVID-19 백신 1차 및 2차 접종 후 항체 반응 비교Comparative Study Published on 2022-03-012022-09-11 Journal: The Korean journal of internal medicine [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 addition Adult patients analyzed antibody formation Antibody Response Antibody responses blood sample Blood samples BNT162b2 BNT162b2 vaccine ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine collected comparable convalescent patient Convalescent patients coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 vaccination COVID-19 vaccine dose enrolled enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay first dose healthcare healthcare worker homologous immune response immune responses Immunity Immunoglobulin Immunoglobulin G Infection intervals Mild mRNA vaccination Patient patients SARS-CoV-2 SARS-CoV-2 variant second dose severe COVID-19 single dose Spike protein the antibody response vaccine platform Vaccines [DOI] 10.3904/kjim.2021.409 PMC 바로가기 [Article Type] Comparative Study
Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single centerChAdOx1 COVID-19 백신 접종 후 중화 항 SARS-CoV-2 항체의 부작용 및 생성: 단일 센터의 단면 연구Article Published on 2022-03-012022-09-12 Journal: Journal of infection and public health [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adverse Adverse reaction anti-SARS-CoV-2 antibody blood sample ChAdOx1 ChAdOx1 vaccine collected coronavirus COVID-19 COVID-19 vaccine cPass™ cross-sectional dose ELISA enrolled event first dose HCW median NAb NAbs Neutralizing Neutralizing antibodies neutralizing antibody response SARS-CoV-2 SARS-CoV-2 NAb second dose significantly higher single center systemic adverse event USA vaccination Vaccine [DOI] 10.1016/j.jiph.2022.02.005 PMC 바로가기 [Article Type] Article